CD19 and colorectal cancer: To mimic this strategy, we developed a retrovirus engineered to express the human CD19 molecules in mouse colorectal cancer cell line CT26 (hCD19+-CT26), which can circumvent the major challenge of identifying antigens that can be safely targeted by CD19-BBζ CAR T cells.